Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (January 2023)
36 slides from Eyepoint's investor presentation, Jan 12, 2023
Slide 1: Investor Presentation January 2023
Investor Presentation January 2023 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activit
Slide 3: EYP-1901 in Phase 2 clinical trials
EYP-1901 in phase 2 clinical trials Bioerodible Durasert® delivering vorolanib, to the posterior segment via a sustained delivery intravitreal (IVT) insert DAVIO 2 - potential 6-month treatment for wet AMD PAVIA - potential 9-month treatment for non-proliferative diabetic retinopathy (NPDR) Vorolani
Slide 4: Durasert Technology: Safe Sustained Intravitreal Drug Delivery
DURASERT® TECHNOLOGY 4 | INVESTOR PRESENTATION Safe Sustained Intravitreal Drug Delivery Used in four of six FDA approved intravitreal sustained delivery products Delivered by a single in-office IVT injection Continuous, stable release of drug Non-Erodible Products YUTIQ® (EyePoint) ILUVIEN® (Alimer
Slide 5: Why Vorolanib?
Vorolanib is a selective and patent protected tyrosine kinase inhibitor (TKI) Intracellular binding of all vascular endothelial growth factor (VEGF) receptors Differentiated mechanism of action versus anti-VEGF biologics that potentially works complementary In-vivo studies demonstrate encouraging ne
Slide 6: Vorolanib binds receptors of all VEGF growth factors
Vorolanib binds receptors of all VEGF growth factors with strong affinity to VEGF receptor 2 - a receptor associated with blood vessel leakage VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1 | Inflammation R2 | Blood Vessel Leakage R3 | Blood Vessel Growth & Leakage 6 | INVESTOR PRESENT
Slide 7: EYP-1901 delivers vorolanib in Bioerodible Durasert
EYP-1901delivers VEGF receptor binding vorolanib in Bioerodible Durasert® EYP-1901 insert only ~1/5000 of vitreous volume EYP-1901 A single IVT injection of up to 3 inserts Bioerodible formulation of Durasert Initial drug burst from surface of insert to rapidly reach therapeutic levels in ocular tis
Slide 8: Phase 1 DAVIO Clinical Trial 12-Month Results
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL 12 MONTH RESULTS 8 | INVESTOR PRESENTATION
Slide 9: Phase 1 DAVIO trial design
EYP-1901 Phase 1 DAVIO clinical trial enrolled 17 patients with previously treated wet AMD over four different dosages Primary Endpoint: Safety Ocular and non-ocular TEAEs through month-12 Secondary Endpoints Supplemental anti-VEGF therapy through 6-months Change in BCVA from baseline CST as measure
Slide 10: DAVIO demonstrated favorable safety at 12 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated favorable overall safety data at 12-months meeting primary endpoint Ocular AEs of particular interest: No vitreous floaters No endophthalmitis No retinal detachment No implant migration in the anterior chamber No retinal vasculitis No posterior segm
Slide 11: Visual acuity and CST stable 12 months after single treatment
EYP-1901: Visual Acuity (VA) and Central Subfield Thickness (CST) Stable 12 Months after Single Treatment For all 17 eyes at 12 months | BCVA = -4.1 letters For all 17 eyes at 12 months | CST on OCT = -2.8 microns AVERAGE CHANGE IN BCVA FROM SCREENING VISIT AVERAGE CHANGE IN CST FROM SCREENING VISIT
Slide 12: 75% reduction in treatment burden at 6 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated clinically significant reduction in treatment burden of 75% at 6-months 12 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –70% Lo
Slide 13: 73% reduction in treatment burden at 12 months
EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 73% at 12-months 13 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –66% Low-
Slide 14: 53% did not require supplemental anti-VEGF at 6 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated that 53% of patients did not require supplemental anti-VEGF treatment at 6-months 35% 47% 41% 41% 71% 76% 35% 35% 53% 82% 82% 100% Median time to supplemental anti-VEGF: 6 months 14 | INVESTOR PRESENTATION
Slide 15: DAVIO trial met all objectives
EYP-1901 Phase 1 DAVIO clinical trial met all objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% supplemental anti-VEGF supplement injection free up to 6-months 75% reduction in treatment burden at 6-months No ocular SAEs reported No drug-rela
Slide 16: Subset analysis: subjects with no excess fluid at screening
DAVIO PHASE 1 CLINICAL TRIAL SUBSET ANALYSIS - SUBJECTS WITH NO EXCESS FLUID AT SCREENING (N=9) 16 | INVESTOR PRESENTATION EYP-1901
Slide 17: Mean change in BCVA and CST, no excess fluid subset
BCVA: best corrected visual acuity Mean change in BCVA from screening visit (n = 9) Mean change in CST from screening visit (n = 9) For 9 eyes at 6 months with no excess fluid at screening BCVA = +1.2 letters at 5 months -0.4 letters at 6 months CST on OCT = +20.8 microns at 5 months -1.0 microns at
Slide 18: 92% reduction in treatment burden at 6 months, no excess fluid
DAVIO Phase 1 clinical trial showed a 92% reduction in treatment burden at 6 months among subjects with no “excess fluid” at screening (n=9) SOC (Anti-VEGF) + EYP-1901 Low dose (n=2) -89% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -100% SOC Anti-VEGF Injections Before and After Tre
Slide 19: 89% reduction in treatment burden at 12 months, no excess fluid
SOC (Anti-VEGF) + EYP-1901 SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit DAVIO Phase 1 clinical trial showed a 89% reduction in treatment burden at 12 months among subjects with no “excess fluid” at screening (n=9) Low
Slide 20: Supplemental injection-free rates in no excess fluid subgroup
Subgroup Analysis: Supplemental Injection-Free Rates Up to Each Visit in Subjects with No Excess Fluid at Screening (n=9) Median time to supplemental anti-VEGF: 12 months 56% 67% 67% 67% 89% 56% 56% 67% DAVIO Final 12-Months Data 100% 100% 100% 100% DAVIO 12-month final data 20 | INVESTOR PRESENTATI
Slide 21: Treat to Maintain
EYP-1901 TREAT TO MAINTAIN 21 | INVESTOR PRESENTATION
Slide 22: Treatment burden reduction supporting treat-to-maintain paradigm
EYP-1901 demonstrated clinically significant reduction in treatment burden of 75% at 6 Months supporting treat to maintain paradigm About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone Another ~30% received only a single supplemental anti-VEGF during 6-months About 15 % failed both
Slide 23: Advancing as complementary Treat-to-Maintain therapy in wet AMD
EYP-1901 advancing as a potential complementary “Treat-to-Maintain” therapy in wet AMD Treat initially with any current anti-VEGF standard-of-care until VA is maximally improved and retina is as dry as possible (induction phase) Maintain with EYP-1901 every six months, supplementing if needed with c
Slide 24: Wet AMD Phase 2 Clinical Trial (DAVIO 2)
WET AMD PHASE 2 CLINICAL TRIAL (DAVIO 2) 24 | INVESTOR PRESENTATION EYP-1901
Slide 25: DAVIO 2 designed to support initiation of Phase 3
The DAVIO 2 clinical trial in wet AMD is designed to support initiation of Phase 3 clinical trials Multi-center randomized Phase 2 clinical trial Three arms Arm 1: 3mg EYP-1901 Arm 2: 2mg EYP-1901 Arm 3: On label aflibercept control Up to 150 patients Only previously treated wet AMD patients to be e
Slide 26: DAVIO 2 randomized, double-masked, aflibercept controlled
EYP-1901 DAVIO 2 clinical trial is randomized, double-masked, aflibercept controlled -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose (n=48) EYP-1901 3mg high dose (n=48) Aflibercept q8W (n=48) RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED EYP-1901 D
Slide 27: NPDR Phase 2 Clinical Trial (PAVIA)
NON-PROLIFERATIVE DIABETIC RETINOPATHY - PHASE 2 CLINICAL TRIAL (PAVIA) 27 | INVESTOR PRESENTATION EYP-1901
Slide 28: Growing Global Diabetic Retinopathy Market
Diabetic Retinopathy Market Size Report. 2018-2020 (GrandViewResearch.com), Global Diabetic Retinopathy Market Size Report. Jan. 2022 (MarketDataForecast.com) Growing Global DR Market $12.27B Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa $12.27 billion
Slide 29: PAVIA trial design
EYP-1901 Phase 2 NPDR PAVIA clinical trial is non-pivotal, randomized double-masked, day-one single injection with sham control evaluating 9 month sustained delivery EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose (n=35) EYP-1901 3mg high dose (
Slide 30: YUTIQ: sustained delivery treatment of posterior segment uveitis
YUTIQ® –A sustained delivery treatment of posterior segment uveitis using Durasert
Slide 31: YUTIQ approval, launch and license agreements
Approved for the treatment of posterior segment uveitis Commercially launched in U.S. in 2019 Patent protection to August 2027 Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years LICENSE AGREEMENTS Alimera Sciences, Inc. has rights for non-infecti
Slide 32: Continuous calm in uveitis: the need and the YUTIQ answer
PRODUCTS 60K–100K patients are suffering from posterior segment uveitis in the U.S. The need Flares can cause blindness 30,000 Americans become blind each year because of uveitis Uveitis lasts a lifetime and often affects people in middle age Conventional treatment is burdensome for patients and car
Slide 33: Continuous 3-year delivery limits blindness-causing flares
PRODUCTS CONTINUOUS CALM IN UVEITIS Continuous 3-year delivery limits blindness-causing flares Time to recurrence of uveitis within 36 months YUTIQ MEDIAN TIME TO FIRST RECURRENCE: 1051 DAYS PROBABILITY RECURRENCE 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 60 120 180 240 300 360 420 480 540 600 6
Slide 34: Record customer demand for YUTIQ in Q4 2022
Record customer demand for YUTIQ in Q4 2022 *Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors. PRODUCTS
Slide 35: Balance Sheet and Financial Summary
Balance Sheet – December 31, 2022 $144 million of cash and investments $40 million of short and long-term debt Cash runway into 2H 2024 Solid cash position and cash runway beyond anticipated 2023 value inflection points FINANCIAL SUMMARY Commercial Performance – 2022 Over $39.5 million of net produc
Slide 36: Investor Presentation January 2023
Investor Presentation January 2023
EyePoint Pharmaceuticals — Investor Presentation (January 2023) on 6ix